Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

EMEND

FOSAPREPITANT DIMEGLUMINE

Standard Dose
EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview EMEND is listed in Drugs@FDA under application 022023 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAPREPITANT DIMEGLUMINE Form and strength POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK AND CO INC Submission history Latest submission status date: 2022-05-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview EMEND is listed in Drugs@FDA under application 022023 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAPREPITANT DIMEGLUMINE Form and strength POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK AND CO INC Submission history Latest submission status date: 2022-05-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.